These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28882013)

  • 1. Antimicrobial management in nosocomial peritonitis: microbiota, drug and time.
    Montero A; Salgado Aranda P; Gilsanz F; Maseda E
    Rev Esp Quimioter; 2017 Sep; 30 Suppl 1():34-38. PubMed ID: 28882013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empiric treatment options in the management of complicated intra-abdominal infections.
    Weigelt JA
    Cleve Clin J Med; 2007 Aug; 74 Suppl 4():S29-37. PubMed ID: 17847176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-resistant bacteria in spontaneous bacterial peritonitis: a new step in management?
    de Mattos AA; Costabeber AM; Lionço LC; Tovo CV
    World J Gastroenterol; 2014 Oct; 20(39):14079-86. PubMed ID: 25339797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Resistant gram-negative bacteria. Therapeutic approach and risk factors].
    Salgado P; Gilsanz F; Maseda E
    Rev Esp Quimioter; 2016 Sep; 29 Suppl 1():26-30. PubMed ID: 27608309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
    Eagye KJ; Kuti JL; Dowzicky M; Nicolau DP
    Clin Ther; 2007 May; 29(5):889-899. PubMed ID: 17697907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
    Kaye KS; Pogue JM
    Pharmacotherapy; 2015 Oct; 35(10):949-62. PubMed ID: 26497481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensively drug-resistant bacteria are an independent predictive factor of mortality in 130 patients with spontaneous bacterial peritonitis or spontaneous bacteremia.
    Alexopoulou A; Vasilieva L; Agiasotelli D; Siranidi K; Pouriki S; Tsiriga A; Toutouza M; Dourakis SP
    World J Gastroenterol; 2016 Apr; 22(15):4049-56. PubMed ID: 27099449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbiological surveillance and antimicrobial stewardship minimise the need for ultrabroad-spectrum combination therapy for treatment of nosocomial infections in a trauma intensive care unit: an audit of an evidence-based empiric antimicrobial policy.
    Ramsamy Y; Muckart DJ; Han KS
    S Afr Med J; 2013 Mar; 103(6):371-6. PubMed ID: 23725954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Complicated intra-abdominal infections: pathogens, resistance. Recommendations of the Infectliga on antbiotic therapy].
    Bodmann KF;
    Chirurg; 2010 Jan; 81(1):38-49. PubMed ID: 20020092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nosocomial spontaneous bacterial peritonitis antibiotic treatment in the era of multi-drug resistance pathogens: A systematic review.
    Fiore M; Maraolo AE; Gentile I; Borgia G; Leone S; Sansone P; Passavanti MB; Aurilio C; Pace MC
    World J Gastroenterol; 2017 Jul; 23(25):4654-4660. PubMed ID: 28740354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
    Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
    Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections--are they applicable today?
    Caínzos M
    Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():9-18. PubMed ID: 19040462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basis for selecting optimum antibiotic regimens for secondary peritonitis.
    Maseda E; Gimenez MJ; Gilsanz F; Aguilar L
    Expert Rev Anti Infect Ther; 2016; 14(1):109-24. PubMed ID: 26568097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.
    Lee YR; McMahan D; McCall C; Perry GK
    Drugs; 2015 Dec; 75(18):2097-117. PubMed ID: 26612473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial.
    Piano S; Fasolato S; Salinas F; Romano A; Tonon M; Morando F; Cavallin M; Gola E; Sticca A; Loregian A; Palù G; Zanus G; Senzolo M; Burra P; Cillo U; Angeli P
    Hepatology; 2016 Apr; 63(4):1299-309. PubMed ID: 26084406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems.
    Tellado JM; Wilson SE
    Surg Infect (Larchmt); 2005; 6(3):329-43. PubMed ID: 16201943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous bacterial peritonitis due to carbapenemase-producing Klebsiella pneumoniae: the last therapeutic challenge.
    Piano S; Romano A; Rosi S; Gatta A; Angeli P
    Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1234-7. PubMed ID: 22713510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates--a multicentre, observational survey in critically ill patients.
    Vogelaers D; De Bels D; Forêt F; Cran S; Gilbert E; Schoonheydt K; Blot S;
    Int J Antimicrob Agents; 2010 Apr; 35(4):375-81. PubMed ID: 20122817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.